In addition, DLX5 methylation may act as a potential marker for distinguishing AML from controls with an AUC of 0.715 analyzed by ROC analysis (95% CI, 0.647‐0.782, P < .001; Figure 3C). This evidence concerns the gene DLX5 and acute myeloid leukemia.